Nota: la ditta di cui al seguente articolo, produce i seguenti radioisotopi:

Isotopo       periodo di dimezzamento

Iodio-123     13,2 ore
Tallio-201     3 giorni
Stronzio-89  50 giorni
Nickel-63     100 anni
Cobalto-58   71 giorni
Cobalto-60   5,2 anni
Iridio-192     74 giorni
Fluoro-18    1,8 ore

September 28, 2000

DENTON, Texas (BW HealthWire) - International Isotopes Inc (NASDAQ/NMS:INIS) (BSE:ITL) (I3) announces that International Isotopes Idaho Inc (I4), the company's wholly owned subsidiary, has received a license from the Nuclear Regulatory Commission (NRC) to begin operating its new Isotope processing facility.

This facility, located in Idaho Falls, Idaho, was first occupied in March of this year and will begin nuclear operations almost immediately. One of the first projects slated for the new facility will involve packaging and handling of irradiated gemstones. I4 will apply the same quality assurance program and experience it uses for several of its reactor and industrial isotope production programs to the gemstone industry. I4 is negotiating an exclusive arrangement with one of the world's largest dealers and distributors of gemstones. Some initial gemstone processing will start on October 1st with a three-month ramp up to full-scale production by the end of 2000. I4 expects the gemstone production business to add about a million dollars per year to company revenues.

Efforts are already underway to amend this NRC license to accommodate the next isotope production projects which are estimated to begin full production by the first quarter 2001. I4 plans to add several other new products into the Isotope processing facility and will eventually transfer the entire existing commercial isotope processing business, currently carried out in a facility leased from the Department of Energy. The company anticipates substantial cost savings by relocating isotope production out of the government facility.

Steve Laflin, Vice President and General Manager of I4, said, "The NRC license for the new Isotope processing facility represents a significant milestone for our business. We are very enthused about this new facility and the added potential this brings to our future business development."

David Camp, President & CEO of I3, said, "When we purchased I4, we knew that it was a great long-term decision. We are beginning to reap the benefits of that decision. In 2001, we expect that I4 will represent 15% of our revenues and over 30% of our gross margin dollars. We congratulate the people at I4 who have worked so hard to obtain these new licenses and very important new business for our company."

About International Isotopes Inc

International Isotopes Inc is initiating production operations to be the premier supplier of finished radiopharmaceuticals, pharmaceutical grade radiochemicals, radioisotopes and brachytherapy devices used in nuclear medicine for the diagnostic and therapeutic treatment of cancer and other diseases.

For More Company Information, Please Visit I3's Web site at:
www.internationalisotopes.com.

International Isotopes Safe Harbor Statement

Statements in the press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the ability to meet time schedules, the need to raise additional capital, the development of competitive products by others and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update statements in this press release.